LNTHLantheus Holdings, Inc.

$100.82

The financials

Lantheus Holdings, Inc. by the numbers

Lantheus Holdings, Inc. (LNTH) reported revenue of $377M in Q1 2026 (quarter ended March 31, 2026), up 1.2% from the same quarter a year earlier. That came with a gross margin of 61% and net income of $118M (31% of revenue). For the full year FY2025, revenue was $1.54B (+0.5% year on year) and net income $234M. Its largest product in 2026-Q2 was PYLARIFY at $240M, 55% of the disclosed total, just ahead of Cardiology at 20%.

Lantheus Holdings, Inc. income statement, Q1 2026 against the same quarter a year earlier
Income statementQ1 2026Q1 2025Change
Revenue$377M$373M+1.2%
Gross profit$231M$238M−2.9%
Operating income$81M$102M−20%
Net income$118M$73M+62%
Diluted EPS$1.80$1.02+76%
Revenue by product, 2026-Q2, as reported to the SEC
ProductRevenueShare
PYLARIFY$240M55%
Cardiology$88M20%
Neuraceq$40M9.0%
Neurology$40M9.0%
Strategic Partnerships And Other$20M4.5%
Licenseand Royalty$11M2.6%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Q2 2026Total $439.0M (+4.5%)
License and Royalty grew +222% year on yearSPECT Business -100% year on year
  • PYLARIFY$240.4MQoQ -0.23%year on year -4.1%
  • Cardiology$88.3MQoQ +4.3%year on year +5.2%
  • Neuraceq$39.6MQoQ +12%year on year -
  • Neurology$39.6MQoQ +12%year on year -
  • Strategic Partnerships And Other$19.9MQoQ +22%year on year +72%
  • License and Royalty$11.2MQoQ +50%year on year +222%
  • License And Royalty Revenues Sales Based Milestone Payment-QoQ -year on year -
  • Other Precision Diagnostics-QoQ -year on year -
  • Other Radiopharmaceutical Oncology-QoQ -year on year -
  • Radiopharmaceutical Oncology-QoQ -year on year -
  • SPECT Business$0.00QoQ -year on year -100%
  • Techne Lite-QoQ -year on year -
  • Total Precision Diagnostics-QoQ -year on year -
Segment sum = 113% of reported consolidated revenue · Latest source: 10-Q filed 2026-08-06, SEC EDGAR